These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 29666949

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.
    Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
    [Abstract] [Full Text] [Related]

  • 6. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A, Casaluce F, Maione P, Gridelli C.
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [Abstract] [Full Text] [Related]

  • 7. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 8. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep 01; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

  • 9. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.
    Russo A, Franchina T, Ricciardi GR, Ferraro G, Scimone A, Bronte G, Russo A, Rolfo C, Adamo V.
    Expert Rev Anticancer Ther; 2016 Jun 01; 16(6):615-23. PubMed ID: 27109446
    [Abstract] [Full Text] [Related]

  • 10. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L, Solomon B.
    Drugs; 2015 Jul 01; 75(10):1059-70. PubMed ID: 26076736
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.
    Hong X, Chen Q, Ding L, Liang Y, Zhou N, Fang W, Chen X, Wu H.
    Oncotarget; 2017 Jun 20; 8(25):41631-41640. PubMed ID: 28427213
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA.
    Cancer Res; 2011 Sep 15; 71(18):6051-60. PubMed ID: 21791641
    [Abstract] [Full Text] [Related]

  • 16. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
    Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR.
    Lancet Oncol; 2011 Oct 15; 12(11):1004-12. PubMed ID: 21933749
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb 15; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.